Novel retroviral constructs

• US 20040002157A1
• Filed: 09/26/2002
• Published: 01/01/2004
• Est. Priority Date: 03/27/1998
• Status: Abandoned Application

• Current Assignee: The Macfarlane Burnet Centre For Medical Research
• Original Assignee: The Macfarlane Burnet Centre For Medical Research
• Inventors: Crowe, Suzanne Mary, Mak, Johnson Chung-Shun, Hill, Melissa Kathleen
• Application Number:
  US10/255,825
• Publication Number:
  US 20040002157A1
• Time in Patent Office: Days
• US Class Current: 435/456
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2740/13043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2740/13052 relating to complementing cells and packaging systems for producing virus or viral particles
• CPC Class Codes: C12N 2740/16043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2740/16052 relating to complementing cells and packaging systems for producing virus or viral particles
• CPC Class Codes: C12N 2830/002 inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
• CPC Class Codes: C12N 2830/75 from invertebrates

Abstract

The present invention relates generally to a method for packaging a gene and genetic constructs useful for same. The method of the present invention represents a new packaging strategy involving vectors comprising retroviral elements and provides for a more efficacious gene therapy and gene modifying protocol. Accordingly, the present invention provides a genetic construct useful as a nucleic acid delivery vector comprising a retroviral packaging signal, a nucleotide sequence derived from viral RNA and which, in RNA form, is translatable to at least one protein and means to facilitate entry of a second nucleotide sequence and wherein said genetic construct, in an RNA form, is capable of being packaged in the presence of retroviral proteins provided in trans with greater efficiency than a genetic construct comprising a packaging signal and said second nucleotide sequence without a nucleotide sequence derived from a retrovirus and which, in RNA form, is capable of translation into a viral protein.

Claims

1. A genetic construct useful as a nucleic acid delivery vector comprising a retroviral packaging signal, a nucleotide sequence derived from viral RNA and which, in RNA form, is translatable to at least one protein and means to facilitate entry of a second nucleotide sequence and wherein said genetic construct, in an RNA form, is capable of being packaged in the presence of retroviral proteins provided in trans with greater efficiency than a genetic construct comprising a packaging signal and said second nucleotide sequence without a nucleotide sequence derived from a retrovirus and which, in RENA form, is capable of translation into a viral protein.

2. A genetic construct according to claim 1 wherein the nucleotide sequence translatable to at least one protein encompasses the gag coding region of a retrovirus.

3. A genetic construct according to claim 1 wherein the nucleotide sequence translatable to at least one protein encompasses the gag and pol coding region of a retrovirus.

4. A genetic construct according to claim 1 wherein means to facilitate entry of the second nucleotide sequence is restriction endonuclease digestion followed by ligation.

5. A genetic construct according to claim 4 wherein means to facilitate entry of a second nucleotide sequence is cleavage of a restriction endonuclease site followed by ligation of the second nucleotide sequence into the site of cleavage.

6. A genetic construct according to claim 1 wherein the nucleic acid delivery vector lacks a functional env coding sequence.

7. A genetic construct according to claim 1 or 6 wherein the nucleic acid delivery vector lacks a functional rev coding sequence.

8. A genetic construct according to claim 1 wherein the second nucleotide sequence corresponds to a gene, anti-sense molecule, co-suppression molecule or ribozyme.

9. A genetic construct useful as a nucleic acid delivery vector comprising a nucleotide sequence derived from viral RNA and which, in RNA form, is translatable to at least one protein or derivative thereof encoded by all or part of the gag region of a retrovirus and means to facilitate entry of a second nucleotide sequence.

10. A genetic construct useful as a nucleic acid delivery vector comprising a nucleotide sequence derived from viral RNA and which, in RNA form, is translatable to at least one protein or derivative thereof encoded by all or part of the gag region of a retrovirus and means to facilitate entry of a second nucleotide sequence and wherein said genetic construct, in an RNA form, is capable of being packaged in the presence of retroviral proteins provided in trans with greater efficiency than a genetic construct comprising a packaging signal and said second nucleotide sequence without a nucleotide sequence derived from a retrovirus and which, in RNA form, is capable of translation into at least one protein or derivative thereof encoded by the gag region.

11. A nucleic acid packaging system comprising at least one vector wherein a first vector comprises a retroviral packaging signal, a nucleotide sequence derived from viral RNA and which, in RNA form, is translatable to at least one protein and means to facilitate entry of a second nucleotide sequence and wherein said genetic construct, in an RNA form, is capable of being packaged in the presence of retroviral proteins provided in trans with greater efficiency than a genetic construct comprising a packaging signal and said second nucleotide sequence without a nucleotide sequence derived from a retrovirus and which, in RNA form, is capable of translation into a viral protein, said retroviral packaging system further comprising at least one other vector or packaging cell wherein said vector or cell'"'"'s genome comprises at least one other retroviral coding region or a functional derivative thereof.

12. A nucleic acid packaging system comprising at least one vector wherein a first vector comprises a retroviral packaging signal, a nucleotide sequence derived from viral RNA and which, in RNA form is translatable to at least one protein and means to facilitate entry of a second nucleotide sequence and wherein said genetic construct, in an RNA form, is capable of being packaged in the presence of retroviral proteins provided in trans with greater efficiency than a genetic construct comprising a packaging signal and said second nucleotide sequence without a nucleotide sequence derived from a retrovirus and which, in RNA form, is capable of translation into a viral protein;

said retroviral packaging system further comprising at least one other vector or packaging cell wherein said vector of cell'"'"'s genome comprises the env region of a virus or a functional equivalent or derivative thereof.

13. A nucleic acid packaging system comprising a First and second vector wherein the first vector is a nucleic acid delivery vector and comprises a retroviral packaging signal, a nucleotide sequence derived from viral RNA and which, in RNA form, is translatable to at least one protein encoded by the gag region of a retrovirus and means to facilitate entry of a second nucleotide sequence;

wherein said second vector comprises the env region of a virus or a functional equivalent or derivative thereof.

14. A nucleic acid packaging system comprising a nucleic acid delivery vector having a retroviral packaging signal, a nucleotide sequence derived from viral RNA and which, in RNA form, is translatable to at least one protein encoded by the gag region of a retrovirus and means to facilitate entry of a second nucleotide sequence and wherein said genetic construct, in an RNA form, is capable of being packaged in the presence of retroviral proteins provided in trans with greater efficiency than a genetic construct comprising a packaging signal and said second nucleotide sequence without a nucleotide sequence derived from a retrovirus and which, in RNA form, is capable of translation into a protein encoded by the gag region of a retrovirus gag protein, and at least one other vector comprising the env coding region of a virus or a functional equivalent or derivative thereof.

15. A retroviral packaging system according to claim 14 wherein said nucleic acid delivery vector encodes at least one Gag protein and at least one Pol protein or functional derivatives thereof.

16. A retroviral packaging system according to claim 14 or 15 wherein the nucleic acid delivery vector comprises the wild-type gag and pol regions of one or more retroviruses.

17. A retroviral packaging system according to claim 14 or 15 or 16 wherein said nucleic acid delivery vector encodes a Rev responsive element (RRE) but does not contain a functional rev.

18. A method for packaging a nucleic acid, said method comprising introducing said nucleic acid into a nucleic acid delivery vector comprising a retroviral packaging signal and a nucleotide sequence derived from viral RNA and which, in RNA form, is translatable to at least one protein and wherein said genetic construct, in an RNA form, is capable of being packaged in the presence of retroviral proteins provided in trans with greater efficiency than a genetic construct comprising a packaging signal and said gene without a nucleotide sequence derived from a retrovirus and which, in RNA form, is capable of translation into a viral protein;

introducing said nucleic acid delivery vector into a cell wherein said cell is capable of providing the genetic material or a protein encoded thereby in trans to permit packaging of said gene into a virion.

19. A method according to claim 18 wherein at least two vectors are used wherein one vector is a nucleic acid delivery vector and at least one other vector carries genetic material required for packaging.

20. A method according to claim 19 wherein the second vector carries all or a functional part of env.

21. A method according to claim 19 or 20 wherein the first vector comprising a nucleic acid delivery vector further comprises (i) gag or a region substantially corresponding to gag, (ii) optionally pol or a region substantially corresponding to pol;

and (iii) a gene of interest.

22. A method for packaging a nucleic acid of interest, said method comprising introducing said nucleic acid into a nucleic acid delivery vector comprising a retroviral packaging signal, gag or a functionally equivalent region thereof and optionally pol or a functionally equivalent region thereof corresponding to pol and introducing said nucleic acid delivery vector into a cell which contains or is capable of containing genetic material or a protein encoded thereby to permit packaging of said gene of interest into a virion.

23. A method according to claim 22 wherein the genetic information required for packaging is provided on at least one plasmid wherein at least one plasmid carries an env region from a retrovirus or a functional equivalent or derivative thereof.

24. Use of the gag region of a retrovirus or a functionally equivalent region thereof in the manufacture of a nucleic acid delivery vector capable of carrying a nucleic acid of interest to be packaged.

25. A gene delivery vector in DNA form comprising all or a functional part of the following:

(i) two retroviral long terminal repeat sequences (LTR) at the two ends of the retroviral DNA genome;

(ii) a primer binding site sequence (PBS);

(iii) a retroviral genomic RNA packaging sequence (ψ

) or equivalent;

(iv) a nucleotide sequence derived from RNA and which, in an RNA form, is translatable to at least one protein;

(v) optionally, a DNA sequence encoding a transcriptional enhancer element;

(vi) a retroviral Rev responsive element or its equivalent;

(vii) a second nucleotide sequence which consists of a genetic construct that is used for gene delivery into the target cells (e.g. see FIG.

     15); and

/or